Pharmacovigilance Consulting: Driving safety and compliance with strategic insight
In the competitive pharmaceutical industry, the pressure to ensure drug safety and regulatory compliance has never been greater. Regulatory expectations are continuously evolving, and a robust pharmacovigilance strategy is key to managing risks and maintaining a trusted reputation.
Our approach to pharmacovigilance consulting ensures that you stay ahead of the curve. By offering end-to-end solutions, we help you mitigate potential risks, ensure ongoing compliance, and maintain the highest standards of patient safety, all while safeguarding your brand’s credibility.
With our expert guidance, you can confidently navigate the regulatory landscape, optimize your safety monitoring systems, and keep patient welfare at the heart of your operations. The result? Reduced risks, a stronger market presence, and peace of mind knowing your products meet the highest safety standards.
Our Core Pharmacovigilance Consulting Services
Navigating the complex world of pharmacovigilance (PV) in China requires more than just compliance, it demands a comprehensive, strategic approach to ensure safety throughout the product lifecycle. At Cisema, we offer end-to-end pharmacovigilance consulting that helps pharmaceutical companies mitigate risks, monitor safety data, and ensure full compliance with Chinese regulations. Our expertise helps you stay ahead in a market where regulatory requirements evolve rapidly, and patient safety is paramount.
In China’s dynamic environment, early detection and management of potential safety signals are crucial. We offer advanced signal detection, assessment, and prioritization services using state-of-the-art analytics and our deep expertise. Our proactive approach helps you identify and address safety risks before they escalate, minimize regulatory scrutiny, and ultimately enhance patient safety, ensuring that your product maintains a trusted reputation in the Chinese market.
China’s regulatory authority demands robust risk management plans (RMPs) and risk minimization strategies for all marketed products. We work with pharmaceutical companies to develop and implement comprehensive RMPs that adhere to both global standards and Chinese regulations. Our proactive risk management approach ensures that you can mitigate potential safety concerns, maintain product integrity, and secure long-term market approval in China’s highly regulated environment.
Timely, accurate reporting of Individual Case Safety Reports (ICSRs) is critical to maintaining regulatory compliance in China. Our team handles the full spectrum of ICSR collection, assessment, and submission, ensuring strict adherence to regulatory timelines. With our in-depth understanding of China’s pharmacovigilance regulations, we help you meet reporting obligations, minimize delays, and maintain a strong regulatory standing, ensuring your product’s ongoing market presence.
For clinical trials in China, safety oversight is paramount. We provide comprehensive safety monitoring, including Serious Adverse Event (SAE) reporting, risk analysis, and compliance management throughout the trial process. Our end-to-end support ensures that regulatory hurdles are minimized, trial safety is prioritized, and your studies run smoothly helping you achieve regulatory approval and patient safety as your top priorities.
In the fast-paced regulatory environment in China, maintaining a robust pharmacovigilance system is essential for ensuring compliance and mitigating risks. Our pharmacovigilance system audits identify gaps in your processes, followed by the implementation of Corrective and Preventive Actions (CAPA) to address these issues. This ensures your pharmacovigilance operations are compliant, efficient, and continuously improving, reducing the risk of non-compliance and streamlining your operations.
In the fast-paced regulatory environment in China, maintaining a robust pharmacovigilance system is essential for ensuring compliance and mitigating risks. Our pharmacovigilance system audits identify gaps in your processes, followed by the implementation of Corrective and Preventive Actions (CAPA) to address these issues. This ensures your pharmacovigilance operations are compliant, efficient, and continuously improving, reducing the risk of non-compliance and streamlining your operations.
Why Partner with Cisema?
Expertise in Navigating China’s Complex Regulatory and Pharmacovigilance Landscape
China’s pharmacovigilance regulations are strict and ever evolving. Our team is deeply attuned to these changes, ensuring your systems are always compliant, audit-ready, and aligned with the latest guidelines. We handle the complexities so you can focus on what matters most: patient safety.
Local Insight, Global Impact
With years of experience in China’s pharmaceutical sector, we offer unparalleled expertise in navigating local regulations. While you work on driving growth and innovation, we ensure your pharmacovigilance systems are fully integrated with the regulatory landscape, keeping you ahead of compliance demands.
Risk Management with a Tailored Approach
No two products are the same, and neither are the risks they face. That’s why we tailor pharmacovigilance strategies to meet the specific needs of your product and market. Our proactive approach identifies and mitigates risks before they impact your regulatory standing, accelerating market access and keeping your operations smooth and compliant.
Client Testimonial
“I am writing to highlight the excellent customer service provided by Jacky Li [Senior Manager at Cisema]. Since I began working with Jacky in August 2023, he has demonstrated exceptional attentiveness and responsiveness, consistently going above and beyond to ensure that our needs are met promptly and effectively. His ability to handle queries and concerns with grace and efficiency is commendable. Moreover, his friendly and approachable demeanor makes every interaction a positive experience.”
— Global biopharmaceutical company headquartered in the USA
Our team is waiting to support you
Submit your Request for Proposal
FAQs about our Pharmacovigilance Consulting Services
Pharmacovigilance consulting is all about ensuring patient safety and maintaining regulatory compliance through comprehensive monitoring, assessment, and reporting of drug safety data across the product lifecycle. At Cisema, we provide expert guidance to navigate the complexities of regulatory landscapes, making sure your pharmacovigilance systems are both effective and compliant.
We provide full support during clinical trials, from adverse event monitoring to safety reporting and literature screening. Cisema ensures that your safety data is accurately collected, analysed, and submitted in line with both Chinese and global regulations, protecting your trial participants and helping you stay on track with regulatory approval timelines.
Periodic Safety Update Reports (PSURs) and Development Safety Update Reports (DSURs) are essential documents that review the risk-benefit profile of a drug. We take care of preparing and submitting these reports, ensuring they meet local regulatory requirements and helping you remain fully compliant.
A QPPV is responsible for overseeing pharmacovigilance systems and ensuring they align with safety regulations. At Cisema, we provide experienced QPPVs to manage your pharmacovigilance activities, offering you 24/7 support and direct communication with regulatory authorities, so you can remain confident in your safety obligations.
Absolutely. We offer localized pharmacovigilance services that include Chinese regulatory submissions, post-marketing safety monitoring, and compliance with the NMPA. Our local expertise helps you seamlessly integrate into China’s unique regulatory environment, ensuring compliance as you grow your presence in the market.
Regulations can shift quickly, and staying ahead of changes is crucial to avoid penalties or delays. We proactively track regulatory updates and provide strategic advice to ensure that your pharmacovigilance systems are always audit-ready and fully compliant with the latest requirements.
Outsourcing your pharmacovigilance to Cisema offers several advantages: it reduces the burden on your internal resources, minimizes compliance risks, and guarantees expert handling of your safety data. Our team brings deep regulatory knowledge, streamlined reporting processes, and tailored solutions that match your needs, giving you peace of mind and allowing you to focus on your core business.
Navigating China’s complex pharmacovigilance landscape requires understanding local regulations, including the NMPA’s specific safety requirements. Cisema provides clear strategies to overcome these challenges, ensuring compliance with post-market surveillance and safety reporting obligations to keep your drug safe and your business on track.
Adverse event reporting in China can be complex due to local regulations and language requirements. Cisema ensures that all adverse events are properly documented, investigated, and reported to the NMPA and other relevant authorities in a timely manner, minimizing risks and ensuring compliance.
Yes. Post-market surveillance is critical for maintaining ongoing compliance and safety monitoring of your products. Cisema helps you set up comprehensive post-market safety monitoring systems, ensuring that your drug continues to meet regulatory standards and patient safety requirements throughout its lifecycle in China.
If your system is found to be non-compliant, the consequences can include regulatory penalties, delays in approval, and even market withdrawal. Cisema helps you remediate compliance gaps, implement corrective actions, and provide continuous support to ensure that your system meets the necessary safety and reporting requirements.
Managing risks is key to protecting both patient safety and your market presence. We work with you to identify potential pharmacovigilance risks, develop risk mitigation strategies, and ensure that your pharmacovigilance systems are robust enough to handle any potential issues that arise.
Continuous improvement is essential for staying compliant and managing drug safety effectively. Cisema offers system audits, training, and ongoing support to ensure your pharmacovigilance systems evolve alongside regulatory changes, industry trends, and emerging safety data.